Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

completed267%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

NCT00443196
withdrawn

Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)

NCT02137811
completedphase_2

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

NCT00243685

Clinical Trials (3)

Showing 3 of 3 trials
NCT00443196Phase 2

Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

Completed
NCT02137811

Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)

Withdrawn
NCT00243685Phase 2

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

Completed

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3